1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,078 | 0,135 | 06.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.05. | Cantargia Publishes Promising Preclinical Results Highlighting CAN10's Potential to Inhibit Vascular Inflammation | 168 | ACCESS Newswire | IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,... ► Artikel lesen | |
| 15.05. | Bulletin from the Annual General Meeting in Cantargia AB | 221 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To discharge... ► Artikel lesen | |
| 13.05. | Cantargia Publishes Interim Report for the First Quarter of 2025 | 358 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The first... ► Artikel lesen | |
| 12.05. | Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 | 183 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort.Model... ► Artikel lesen | |
| 06.05. | Cantargia's Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors | 214 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indications... ► Artikel lesen | |
| 29.04. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2025 | 199 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025... ► Artikel lesen | |
| 29.04. | Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 | 164 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 28.04. | Cantargia Announces the Publication of Preclinical Data Highlighting Nadunolimab's Potential to Counteract Tumor-Driven Systemic Immunosuppression | 93 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 28, 2025 / Cantargia (STO:CANTA)Preclinical data shows IL1 family signals mediate systemic immune suppression.Blocking IL1RAP can overcome resistance to immune therapy... ► Artikel lesen | |
| 25.04. | Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR | 346 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention... ► Artikel lesen | |
| 25.04. | Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference | 394 | ACCESS Newswire | Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvironment... ► Artikel lesen | |
| 11.04. | Cantargia Publishes Annual Report 2024 | 278 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The... ► Artikel lesen | |
| 11.04. | Notice of Annual General Meeting in Cantargia AB | 253 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Ideon... ► Artikel lesen | |
| 01.04. | Cantargia appoints Morten Lind Jensen as Chief Medical Officer | 228 | ACCESS Newswire | LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as Chief... ► Artikel lesen | |
| 25.03. | Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab | 453 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clinical... ► Artikel lesen | |
| 25.03. | Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025 | 314 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the development... ► Artikel lesen | |
| 13.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 444 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participate... ► Artikel lesen | |
| 12.03. | Cantargia (OMX: CANTA) enrols first patient in leukaemia study | 331 | Edison Investment Research | Cantargia has confirmed that the first patient has been in enrolled in the study assessing nadunolimab in leukaemia. More specifically, this is an investigator-initiated, open-label, Phase Ib/IIa clinical... ► Artikel lesen | |
| 12.03. | First Patient Enrolled in Cantargia's Leukemia Study with nadunolimab | 416 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA)Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA)... ► Artikel lesen | |
| 10.03. | Cantargia (OMX: CANTA) breast cancer study fully recruited | 322 | Edison Investment Research | Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy,... ► Artikel lesen | |
| 10.03. | Cantargia's TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited | 253 | ACCESS Newswire | TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia AB)... ► Artikel lesen |
1 2 3 Weiter >>
52 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,35 | +0,05 % | BioNTech SE: BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt | BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard... ► Artikel lesen | |
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 434,60 | +0,44 % | Regeneron-Aktie crasht nach COPD-Daten - Verona Pharma schießt auf Allzeithoch | Bittere Pille für Regeneron Pharmaceuticals. Das Unternehmen und der Entwicklungspartner Sanofi haben in der vergangenen Handelswoche mit frischen Spätphasen-Studiendaten zum COPD-Hoffnungsträger Itepekimab... ► Artikel lesen | |
| BRAIN BIOTECH | 2,100 | +0,48 % | BRAIN Biotech: Wann kommt die Trendwende bei den Biokatalysatoren? | Die BRAIN Biotech AG (DE0005203947) kämpft mit einem schwierigen Marktumfeld. Im ersten Halbjahr 2024/25 ging der Umsatz um 7,2 Prozent auf 25,2 Millionen Euro zurück. Das Unternehmen spürt die Auswirkungen... ► Artikel lesen | |
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
| BURCON NUTRASCIENCE | 0,073 | +5,80 % | Burcon NutraScience Corporation: Burcon to Participate in 2025 Canadian Climate Investor Conference | Vancouver, British Columbia--(Newsfile Corp. - May 28, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development of... ► Artikel lesen | |
| CSL | 136,82 | -1,03 % | CSL LIMITED: Notification of cessation of securities - CSL | ||
| MANNKIND | 3,790 | -1,28 % | MannKind bei Jefferies Global Healthcare: Strategisches Wachstum und Innovation | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,434 | +0,99 % | Oxford Nanopore Tech - Changes in Composition of Remuneration Committee | ||
| OCULAR THERAPEUTIX | 7,840 | -1,01 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular"), a biopharmaceutical company committed to redefining the retina experience, today announced that... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,250 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Reports Q1 Financial Results and Provides Business Update | TECELRA® launch 2025 YTD metrics: 28 ATCs available; 21 patients aphresed; and 14 doses invoiced$4.0 million Tecelra net sales in Q1 2025Instituting 2025 Tecelra full year sales guidance of $35-$45... ► Artikel lesen | |
| CODEXIS | 2,000 | -3,66 % | Codexis, Inc.: Codexis Announces New Employment Inducement Grants | REDWOOD CITY, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced... ► Artikel lesen | |
| TELO GENOMICS | 0,050 | -11,50 % | Telo Genomics Corp.: Telo Genomics Receives New Client Tier under Intellectual Property Ontario (IPON) | Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,076 Euro und damit -18,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.